Merck &
At a glance
Merck & reported 2025 revenue of $65.01B, up 1.3% from $64.17B in 2024. Over 4 years since 2021 ($48.7B), that is growth of about 7.5% a year. 2025 was the highest revenue year in this period.
In the last 12 months 11 insiders reported 0 open-market purchases and 21 sales ($72M). None of the sales were flagged as 10b5-1 plan trades. The largest was a sale of $14.5M by EVP, General Counsel Jennifer Zachary on Feb 9, 2026.
Merck & filed 8 current reports (Form 8-K) in the last 12 months, most often for results of operations (4), other events (2), officer or director change (1) and shareholder vote results (1). The latest officer or director change was reported on Oct 13, 2026.
2 of the 20 investors tracked here held Merck & at the last quarter end, worth $748.1M combined. It is the largest weight for National Pension Service (Korea) (0.5% of its portfolio), followed by Bridgewater Associates (0%). New this quarter: Bridgewater Associates.
Annual results
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net income | $12.35B | $14.52B | $365M | $17.12B | $18.25B |
| Diluted EPS | $5.14 | $5.71 | $0.14 | $6.74 | $7.28 |
| Dividend per share | $2.64 | $2.80 | $2.96 | $3.12 | $3.28 |
Fiscal year ends Dec 31 · incorporated in NJ
Tracked investors holding (13F)
Weight is the share of each investor's portfolio, as of the quarter end.
Current reports (8-K, last 12 months)
Insider open-market trades (last 12 months)
Source: SEC EDGAR. How figures are combined